BNTX PE is well undervalued compared to Moderna, which is unjustified because BNTX financials are twice as better than Moderna. The street knows this. The recent run up, I originally thought, was the PE being adjusted. But now, I simply believe the vaccine stocks simply run up and down together. The wild card is Novavax, which if/when approved, will hurt this and Moderna even though American manufacturing for Novavax has been below what the FDA requires in purity (this was reported and it’s unknown whether Novavax has fixed its quality control problems).

$BioNTech SE(BNTX)$ $Novavax(NVAX)$ $Moderna, Inc.(MRNA)$